eXoZymes Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
N-trans-caffeoyltyramine (NCT) Production Scale Quarterly100.0Target: Tonnage commercial scale
Quarterly Net Loss Quarterly-2.4MTarget: Path to breakeven by 2028
Cash and Cash Equivalents Quarterly1.4MTarget: Sufficient runway with June 2026 public offering proceeds
Watch Items
- Warrant Exercise Price Reset TriggerTrigger: Equity issuance below $8.99 per share before June 5, 2027Action: Monitor dilutive impact as warrant exercise price resets to $0.001 per share
- NCT Commercialization and Human StudiesTrigger: Initiation of human studies and GRAS certification progressAction: Evaluate regulatory timelines and commercial partner engagement
Research as of 19 Jun 2026